Statin drugs have made history for their blockbuster sales, and their use is only expected to increase when Lipitor's patent soon expires. But, for millions of people, statins simply don't do enough. Melinda Wenner Moyer explores ongoing efforts to develop new cholesterol-lowering drugs in light of clues that cardiovascular health is more complicated than doctors once thought.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wenner Moyer, M. The search beyond statins. Nat Med 16, 150–153 (2010). https://doi.org/10.1038/nm0210-150
Issue Date:
DOI: https://doi.org/10.1038/nm0210-150
This article is cited by
-
Caenorhabditis elegans pathways that surveil and defend mitochondria
Nature (2014)
-
Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
Clinical Pharmacology & Therapeutics (2012)
-
Drug targets beyond HMG-CoA reductase: Why venture beyond the statins?
Frontiers in Biology (2011)